Abstract
NLRP1 is predominantly overexpressed in breast cancer tissue, and the evaluated activation of NLRP1 inflammasome is associated with tumor growth, angiogenesis, and metastasis. Therefore, targeting NLRP1 activation could be a crucial strategy in anticancer therapy. In this study, we investigated the hypothesis that NLRP1 pathway may contribute to the cytotoxic effects of celecoxib and nimesulide in MDA-MB-231 cells. First of all, IC50 values and inhibitory effects on the colony-forming ability of drugs were evaluated in cells. Then, the alterations in the expression levels of NLRP1 inflammasome components induced by drugs were investigated. Subsequently, the release of inflammatory cytokine IL-1β and the activity of caspase-1 in drug-treated cells were measured. According to our results, celecoxib and nimesulide selectively inhibited the viability of MDA-MB-231 cells. These drugs remarkably inhibited the colony-forming ability of cells. The expression levels of NLRP1 inflammasome components decreased in celecoxib-treated cells, accompanied by decreased caspase-1 activity and IL-1β release. In contrast, nimesulide treatment led to the upregulation of the related protein expressions with unchanged caspase-1 activity and increased IL-1β secretion. Our results indicated that the NLRP1 inflammasome pathway might contribute to the antiproliferative effects of celecoxib in MDA-MB-231 cells but is not a crucial mechanism for nimesulide.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Breast cancer remains a significant cause of mortality among women worldwide, with a consistently increasing incidence rate. Significant advancements in anticancer treatments have notably improved outcomes for patients. However, difficulties must be overcome to enhance therapeutic effectiveness and prevent adverse effects, particularly in triple-negative breast cancer (Carey et al. 2006). Therefore, it is crucial to present effective therapeutic strategies by searching for novel pharmacological mechanisms and targets, including new drugs and repurposing existing ones (Masoud and Pagès 2017).
Inflammasomes are crucial components of the innate immune system and have a critical function in protecting organisms against cellular stress, infections, and tissue damage. However, numerous studies have revealed that chronic inflammation and inflammasomes are notably associated with the development of various diseases, including cancer, neurodegenerative disorders, obesity, diabetes, atherosclerosis, and ulcerative colitis (Strowig et al. 2012). Recently, there has been a growing interest in investigating the potential contributions of inflammasomes to tumor development, progression, and metastasis (Karki and Kanneganti 2019). Interestingly, the role of inflammasomes in tumorigenesis and carcinogenesis is still controversial due to their tumor-promoting or suppressing effects, depending on the type of inflammasome and cancer (Thi and Hong 2017). Inflammasome-derived components may protect against colitis-associated colon cancer (Sharma and Kanneganti 2023). However, various reports indicate that inflammasomes may promote tumor growth in breast, lung, and skin cancer (Kantono and Guo 2017).
In breast cancer, the excessive activation of certain types of inflammasomes is associated with carcinogenesis, metastasis, and recurrence (Guo et al. 2016). In particular, the contribution of the NLRP1 inflammasome pathway to the development and progression of breast cancer is noteworthy (Wei et al. 2017). The activation of NLRP1 inflammasome, consisting of NLRP1, ASC adapter protein, and pro-caspase-1 effector protein, results in caspase-1 activation. Upon activation, caspase-1 triggers the release of IL-1β and IL-18, leading to pyroptosis in the cell (Taabazuing et al. 2020). In breast cancer tissues, expression levels of NLRP1 are substantially upregulated (Guo et al. 2016). The overexpression of NLRP1 and increased levels of IL-1β in the tumor microenvironment have been emphasized to promote breast cancer malignity, progression, and migration (Elaraj et al. 2006; Wei et al. 2017). Therefore, targeting the NLRP1 inflammasome pathway represents a novel therapeutic approach.
It has been reported for over 20 years that COX inhibitors, specifically COX-2 selective inhibitors, may have anticancer properties. COX-2 is frequently overexpressed in various human malignant tumors, including breast cancer, similar to NLRP1 (Díaz-Cruz et al. 2005). The increased COX-2 expression level is associated with breast tumor growth rate and malignancy, as well as hyperproliferation, angiogenesis, and metastasis (Costa et al. 2002; Liu et al. 2001). Celecoxib, a potent COX-2 enzyme inhibitor, and nimesulide, a preferential COX-2 inhibitor, are frequently prescribed due to their analgesic and anti-inflammatory properties (Bennett and Villa 2000; Derry and Moore 2013). It has been shown that celecoxib suppresses cancer cell proliferation and reduces cancer incidence by numerous preclinical, clinical, and epidemiological studies (Ashok et al. 2011; Lanza-Jacoby et al. 2013; Woditschka et al. 2008). Previous investigations provide compelling results that also nimesulide could suppress tumor growth (Eibl et al. 2003; Hida et al. 2000; Li et al. 2003; Pan et al. 2003). Several COX-2-dependent or -independent mechanisms have been proposed for the antiproliferative effects of celecoxib and nimesulide (Chen et al. 2009; Li et al. 2018; Nakatsugi et al. 2000; Shaik et al. 2004; Wen et al. 2020); however, the current understanding of the precise mechanisms underlying the anticancer potential of relevant drugs is limited. The expression of COX-2 can be induced by inflammatory cytokines released due to inflammasome activation (Kuwano et al. 2004). Additionally, suppressing COX-2 enzyme activity or expression reduces NLRP3 inflammasome activation, serum IL-1β, and caspase-1 activity in cells (Hua et al. 2015). Besides NLRP3, COX-2 inhibitors may have anticancer effects by inhibiting the inflammatory activation of NLRP1, which is predominantly highly expressed in breast cancer tissue. However, comprehensive studies investigating the role of NLRP1 activation in the antiproliferative effects of COX-2 inhibitors in breast cancer are limited.
In the present study, we hypothesized that the NLRP1 inflammasome pathway may be involved in the antiproliferative and cytotoxic effects of celecoxib in the MDA-MB-231 cells. Nimesulide was included in the study to compare its results with celecoxib, which has higher COX-2 selectivity. We first determined cytotoxic effects of drugs via WST-1 and colony formation assay. Then, we investigated alterations induced by celecoxib or nimesulide in the expression levels of NLRP1 inflammasome components. Finally, we measured the caspase-1 activity and IL-1β secretion of each drug-treated cell.
Materials and methods
Cell culture and materials
MDA-MB-231, a triple-negative breast cancer cell line (ATTC HTB-26, USA), MCF-7, the estrogen receptor (ER)-positive human breast cancer cell line (ATTC HTB-22, USA), SK-BR-3, human epidermal growth factor receptor 2 (HER2)-positive breast cancer cell line (ATTC HTB-30, USA), and MCF-10A, a non-tumorigenic epithelial cell line (ATTC CRL-10317, USA), were maintained at 37 °C in a 5% CO2 atmosphere. Breast cancer cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. MCF-10A cell line was cultured in Lonza Mammary Epithelial Cell Medium (Lonza/Clonetics, USA) enriched with MEGMTM SingleQuot Kit (Lonza). The cells were regularly monitored with the inverted microscope, and subculturing protocols were applied when they reached 80% confluence. Anti-NLRP1, anti-cleaved caspase-1, anti-ASC, and anti-β-actin antibodies were obtained from the Cell Signaling (Ann Arbor, MI). The COX activity kit (MAK414) and IL-1β ELISA kit (RAB0273) were acquired from Sigma-Aldrich (St. Louis, MO), and caspase-1 activity kit (ab39412) was purchased from Abcam (MA, USA). Celecoxib and nimesulide were kindly provided by Deva Pharmaceutical Company (Turkey). All other chemicals and materials were obtained from Sigma-Aldrich (St. Louis, MO).
Preparation of drug solutions
Celecoxib and nimesulide were dissolved in DMSO to prepare leading stock solutions of 10 mM. Then, stock solutions were diluted with the appropriate volume of medium, and cells were incubated at the desired final concentrations of drugs. The maximum DMSO concentration did not exceed 0.1% (v/v).
Determination of cytotoxicity of drugs by WST-1 assay
MDA-MB-231 and MCF-10A cells (two independent cultures) were seeded into 96-well plates (0.6 × 104 cells/well). Following overnight, the cells were treated with increasing concentrations of each drug (0–100 µM for MDA-MB-231 cells and 0–400 µM for MCF-10A cells) for 48 h. The cells exposed to 0.1% DMSO were used as a control. At the end of the incubation, the WST-1 assay protocol was performed in accordance with the previous studies (Jia et al. 2014). Untreated and treated cells were incubated with the 10 µl WST-1 reagent for 3 h at 37 °C. The absorbance was measured using a Varioskan microplate reader at 430 nm. The cell viability was calculated as a percentage of the untreated control. IC50 values were calculated using GraphPad Version. Fifty percent, 75%, and 25% inhibitory concentration (IC50, IC75, and IC25) values were calculated using GraphPad Prism software 8.4 (GraphPad, San Diego, CA). Selectivity indices (SI) were calculated from the IC50 ratio of MCF-10A to MDA-MB-231 cells.
Colony formation assay
The colony formation assay determines an agent’s long-term cytotoxic effects by measuring a single cell’s colony formation ability (Elangovan et al. 2008). MDA-MB-231 cells were seeded in a 6-well plate at 500 cells/well and allowed to attach for 24 h. Then, each drug was added into wells at three doses (IC25, IC50, and IC75). Following the incubation period (14 days), the medium was removed, and the wells were washed with PBS. Cells were fixed using 70% ethanol. Subsequently, the wells were incubated with 1.25% crystal violet for 1 h. Finally, the stained colonies were counted using an inverted microscope, and the number of colonies was compared with the control (% 0.1 DMSO) (Elangovan et al. 2008).
Western blotting
Initially, a western blot analysis was conducted to compare the levels of NLRP1 protein in various breast cancer cell lines with that of MCF-10A, a healthy cell line. Then, the effects of drugs on the expression levels of NLRP1, ASC, and cleaved caspase-1 proteins in MDA-MB-231 cells were investigated. Cells (3 × 105 cells/well) were treated with drugs at IC50 concentration for 48 h. After incubation, the cells were harvested and lysed with RIPA buffer containing a 1% protease inhibitor cocktail. The protein contents were measured by Bradford agent (Bradford 1976). Cellular proteins (30 µg) were separated with SDS-PAGE at 120 V and transferred to PVDF membranes at 100 mV for 2 h at + 4 °C. Membranes were blocked with 5% milk powder for 1 h. Then, membranes were incubated with anti-NLRP1, anti-cleaved-caspase-1, anti-ASC, anti-cleaved-caspase-1, or anti-β-actin, followed by incubation with secondary antibodies. Vilber Lourmat Fusion FX7 system was used to reveal the protein bands through enhanced chemiluminescence. Relative protein levels were normalized to β-actin (Zhai et al. 2017).
IL-1β release
MDA-MB-231 cells were treated with different concentrations of drugs (IC25, IC50, and IC75) for 48 h. The levels of IL-1β released into the medium were measured using an ELISA assay following the commercial kit protocol. For this purpose, at the end of the incubation period, the supernatant in the wells was collected and applied to wells coated with a monoclonal antibody for IL-1β. Biotinylated anti-IL-1β was added to the standards and samples, followed by 3 h of incubation at room temperature. Subsequently, the wells were washed, streptavidin HRP was added, and the second incubation step was started for 30 min at room temperature. Then, the wells were washed, and chromogen TMB was added. After 20 min, stopper solution was added, and the absorbance was measured at 450 nm by a microplate reader. The intensity of absorbance directly reflects the concentration of IL-1β (Escobar et al. 2015).
Statistical analyses
Experiments were repeated three times and performed in triplicate. Data was expressed as mean ± SD. Kolmogorov–Smirnov was performed as a normality test. Statistical differences were analyzed using one-way ANOVA, following Dunnett’s post hoc test. p < 0.05 was considered statistically significant.
Results
Cytotoxic effects of celecoxib and nimesulide on MDA-MB-231
The cell viability assay was performed to assess the cytotoxic potential of each drug and determine the working concentrations for further studies. Hence, MDA-MB-231 and MCF-10A cells were treated with increasing concentrations of celecoxib or nimesulide, and IC25, IC50, and IC75 values were calculated using GraphPad (Table 1). Both drugs exhibited dose-dependent cytotoxicity on MDA-MB-231 cells; however, they were non-toxic to MCF-10A cells at dose levels below 200 µM. As shown in Fig. 1, celecoxib and nimesulide inhibited cell viability of MDA-MB-231 cells with IC50 values of 25.2 ± 1.117 µM and 34.7 ± 1.02 µM, respectively (Fig. 1a, c).
These drugs exhibited selective cytotoxicity towards breast cancer cells, as supported by the significantly (p < 0.05) higher IC50 values of MCF-10A (celecoxib; 264.6 ± 0.916 µM and nimesulide; 338.4 ± 1.245 µM) compared to MDA-MB-231 cells. The SI ratios of celecoxib and nimesulide were 10.02 and 9.8, respectively (Table 1). In addition to IC50, we calculated the IC25 and IC75 values of each drug in MDA-MB-231 cells to perform assays under slight or high cytotoxicity conditions and investigate dose dependency (Table 1).
Celecoxib and nimesulide decreased the colony formation potentials of MDA-MB-231 cells
The colony-forming ability of MDA-MB-231 cells was evaluated following treatment with celecoxib or nimesulide to observe the long-term effects of the compounds. For this purpose, cells were exposed to each drug for 14 days at three dose levels (IC25, IC50, and IC75). At the end of the period, the number of colonies was normalized to the control. As shown in Fig. 2, both drugs significantly reduced the proliferation rate of MDA-MB-231 cells. The number of colonies decreased by 29% and 67% with celecoxib concentrations of IC25 and IC50, respectively. Treatment with nimesulide at IC25 and IC50 concentrations resulted in a 22% and 67.3% reduction in colony numbers, respectively. It was observed that exposure to IC75 doses of drugs almost wholly inhibited the colony-forming ability of cells.
Western blot analyses
The results from the western blot analysis revealed that the level of NLRP1 protein expression was significantly upregulated in MDA-MB-231 cells (Fig. 3a) compared to the healthy cell line. Indeed, the NLRP1 protein expression in MDA-MB-231 cells was found to be approximately 15.1 times higher than in MCF-10A cells (Fig. 3b). When other breast cancer cell lines were examined, it was observed that SK-BR-3 cells expressed NLRP1 protein in almost similar amounts as healthy breast epithelial cells. In addition, the expression level of NLRP1 in MCF-7 cells was around 5.2 times higher than in MCF-10 cells (Fig. 3b). The significant upregulation of NLRP1 protein levels in MDA-MB-231 cells suggests that the NLRP1 inflammasome pathway may be a potential therapeutic target for triple-negative breast cancer. Therefore, we investigated whether the NLRP1 inflammasome signaling pathway plays a role in the antiproliferative effects of these drugs in MDA-MB-231 cells. First, we determined the respective effects of both drugs on the expression of NLRP1 inflammasome components: NLRP1, ASC, and cleaved-caspase-1. For this purpose, the cells were incubated with each drug for 48 h, and then western blot analysis was performed.
The expression of NLRP1 was remarkably downregulated by celecoxib at IC50 concentration after 48 h. Celecoxib induced about 48.4% reduction of NLRP1 protein expression in MDA-MB-231 cells (Fig. 3d). Additionally, the drug significantly decreased the expression of cleaved caspase-1 and ASC, which are considered other significant components of the NLRP1 inflammasome (Fig. 3e, f). Celecoxib reduced caspase-1 expression by 43.2% and ASC expression by 6.3%. Surprisingly, the expression levels of all three proteins were upregulated by nimesulide (IC50). Treatment with nimesulide led to a 12.4% increase in NLRP1 expression, a 41.8% increase in caspase-1 expression, and a 98% increase in ASC expression (Fig. 3). Our findings indicate that celecoxib reduces the expression levels of NLRP1 inflammasomal components and may inhibit its activation. However, the findings of nimesulide were unexpected.
Effects of celecoxib and nimesulide on caspase-1 enzyme activity
Figure 4 demonstrates the caspase-1 activities of MDA-MB-231 cells treated with increasing concentrations of celecoxib or nimesulide for 48 h. Based on the results, the activity of caspase-1 was dramatically inhibited by celecoxib compared to control cells. Celecoxib at IC25, IC50, and IC75 concentrations reduced enzyme activity by 19%, 46%, and 68%, respectively. The inhibition of caspase-1 activity was associated with lower protein expression of NLRP1, cleaved caspase-1, and ASC. It seems that the downregulation of cleaved caspase-1 leads to the inhibition of caspase-1 activity by celecoxib (Fig. 3). By contrast, exposure to nimesulide did not result in remarkable alterations in caspase-1 activity in cells (Fig. 4a). This observation was inconsistent with the increase in cleaved caspase-1 expression level induced by nimesulide (Fig. 3).
Effects of celecoxib and nimesulide on IL-1β secretion
Figure 5 represents the levels of IL-1β in untreated or treated cell supernatants. Both drugs have remarkably decreased the release of IL-1β. The concentrations of IL-1β were reduced by 19.7% and 39.5% with celecoxib and nimesulide, respectively, at their IC50 concentrations (Fig. 5).
Importantly, we also observed that celecoxib decreased the protein levels of NLRP1 inflammasome components and activity of caspase-1 (Figs. 3 and 4). All results together suggest that celecoxib inhibits the activation of NLRP1 inflammasome, which may play a role in its anti-proliferative effects. However, there was no clear relationship between decreased IL-1β levels, unchanged caspase-1 activity, upregulation of NLRP1, and cleaved caspase-1 proteins (Figs. 3 and 4).
Discussion
Inflammation has emerged as a substantial target of cancer treatment and prevention due to its tumor-promoting effect (Landskron et al. 2014). Cancer cells may use specific components of the inflammatory pathways to prevent apoptosis and promote proliferation, angiogenesis, and metastasis. The pro-inflammatory cytokines have been demonstrated as signalling molecules contributing to metastasis by promoting breast cancer cells to penetrate blood vessels (Coussens and Werb 2002). COX-2 and inflammasomes, among various inflammation-related factors, are frequently targeted for anti-inflammatory and anticancer treatments (Alle and Jones 2015; Díaz-Cruz et al. 2005). Celecoxib, a specific COX-2 inhibitor, was proven to exhibit chemopreventive and anticancer activity in several preclinical studies and clinical trials (Basu et al. 2005; Brandão et al. 2013; Bocca et al. 2011; Dai et al. 2012; Woditschka et al. 2008; Lanza-Jacoby et al. 2003). Surprisingly, there are limited studies investigating the anti-antiproliferative effects of nimesulide (Chen et al. 2009; Nakatsugi et al. 2000; Shaik et al. 2004). In our study, celecoxib and nimesulide were found to inhibit the cell viability of MDA-MB-231 in a concentration-dependent manner after 48-h exposure, as expected (Fig. 1). In addition, the colony-forming ability of MDA-MB-231 cells was significantly reduced after treatment with increasing doses of each drug (Fig. 2). We included nimesulide in our study to compare the results of two drugs with different COX-2 inhibition selectivity.
In normal breast tissue, COX-2 is undetectable. However, it is overexpressed by approximately 40% in tumor tissue (Bosco et al. 2011). The overexpression of COX-2 increases by 80% in ductal carcinoma in situ (Díaz-Cruz et al. 2005). The elevated expression level of COX-2 is associated with tumor size, malignancy, and metastasis to lymph nodes and lungs (Díaz-Cruz et al. 2005; Liu et al. 2001). Hence, targeting COX-2 and studying the potential of COX-2 inhibitors for breast cancer therapy is a promising strategy. Bocca et al. demonstrated that celecoxib led to inadequate inhibition of COX-2 in MCF-7 (ER +) cells while inducing a significant antiproliferative effect through ERK/AKT and other contributing mechanisms (Bocca et al. 2011). However, in MDA-MB-231 cells (triple negative), strong suppression of COX-2 was shown to be associated with inhibition of cell growth. Numerous studies indicate that COX-2 expression is higher in MDA-MB-231 cells than in less invasive cells (Basu et al. 2005). Different mechanisms may play a role in the antiproliferative effects of celecoxib depending on the cell line due to invasiveness and COX-2 levels (Li et al. 2018). Therefore, we restricted our investigation to studying only with a triple-negative cell line. Consistent with previous studies, we demonstrated that both drugs exhibit selective and significant cytotoxicity in MDA-MB-231 cells (Fig. 1) and almost wholly inhibit COX-2 activity at the dose levels we studied. The IC50 values for inhibition of COX-2 activity were 0.343 and 0.56 µM for celecoxib and nimesulide, respectively (data not shown).
Although the efficacy of celecoxib has been encouraging, the mechanisms of its antitumor action still require investigation. Several mechanisms have been proposed for the antitumor effects of celecoxib, including cytokine-driven upregulation of PGE-synthase-1, regulation of tumor microenvironment, and induction of cell death pathways (Li et al. 2018; Wen et al. 2020). However, there are still questions regarding the exact mechanism underlying its antiproliferative properties (Li et al. 2018). Moreover, the role of NLRP1 inflammasome in the antitumor mechanism of celecoxib is unknown. The current study aimed to demonstrate whether NLRP1 inflammation is involved in the anticancer mechanism of celecoxib and nimesulide in MDA-MB-231 cells.
NLRP1 has been demonstrated to increase the growth of cancer cells by inducing inflammasome activation and suppressing apoptotic pathways (Zhai et al. 2017). Wei et al. reported that NLRP1 was overexpressed in 83% of primary breast cancer tissue. In that study, researchers evaluated the correlation between the expression of NLRP1 and various pathological characteristics of breast cancer patients. NLRP1 protein was indicated to be overexpressed in all human breast cancer subtypes, and a significant association between increased NLRP1 levels and lymph node metastasis was demonstrated. Moreover, it was revealed that NLRP1-overexpressing MCF-7 cells exhibited a high rate of proliferation, migration, and invasion (Wei et al. 2017). Hence, the excessive NLRP1 inflammasome activation may promote tumorigenesis and carcinogenesis in breast tissue. However, cell-based investigations were limited to MCF-7 cells in that study. Therefore, further research is required to explore the NLRP1 expression in MDA-MB-231 cells and its role in the pathogenesis and treatment of triple-negative breast cancer. Our study has demonstrated that NLRP1 protein is slightly expressed in normal breast tissue, while its level was significantly upregulated in MCF-7 cells, as indicated by Wei et al. Surprisingly, the overexpression of NLRP1 was much more pronounced in MDA-MB-231 cells than in MCF-7 cells (Fig. 3b), suggesting that NLRP1 may be a potential therapeutic target in the treatment of triple-negative breast cancer as well as ER ( +) breast cancer.
After demonstrating the expression of NLRP1 protein in three different breast cancer cells and highlighting its dramatic upregulation in MDA-MB-231 cells, we investigated whether COX-2 enzyme inhibitors affect the expression of NLRP1 inflammasomal components in MDA-MB-231 cells. Our results revealed that celecoxib treatment at IC50 concentration downregulated NLRP1, pro-caspase-1, and ASC expression in MDA-MB-231 cells (p < 0.05) (Fig. 3c). In cancer, excessive NLRP1 activation has been linked to altered protein expression and changes in genes encoding inflammatory pathways (Ciążyńska et al. 2020). Therefore, agents inhibiting mRNA or protein expression of inflammasome components reduce NLRP1 activation and the inflammatory response in the tumor microenvironment. In our study, the decreased protein levels of NLRP1, pro-caspase-1, and ASC induced by celecoxib (IC50) may be related to the drug’s cytotoxic effect. Contrary to celecoxib, nimesulide induced the levels of NLRP1, cleaved caspase-1, and ASC in MDA-MB-231 cells (Fig. 3c). This finding was surprising because we expected nimesulide may also downregulate NLRP1, suggesting that celecoxib and nimesulide have different mechanisms of antiproliferative effects on triple-negative breast cancer cells.
Caspase-1 is the main effector protein of NLRP1 inflammasome and is required for the maturation of pro-IL-1β to IL-1β (Franchi et al. 2009). Inflammasome-mediated caspase-1 activation plays a crucial role in regulating the expression of pro-inflammatory genes or apoptotic pathways, making caspase-1 an essential factor in the pathogenesis and treatment of various diseases, including cancer (Lillo and Saleh 2022). However, various developed reagents targeting caspase-1 have limited use due to off-target effects and adverse effects due to extreme prevention of inflammasome activities (Green and Kroemer 2005). In our study, celecoxib inhibited caspase-1 activity in a dose-dependent manner (Fig. 4), which is consistent with a decrease in caspase-1 expression levels (Fig. 3). The activity of caspase-1 remained unchanged with nimesulide treatment, even at IC75 concentrations. This data suggests that nimesulide induces the expression of caspase-1 but does not alter its activity.
Increased levels of the pro-inflammatory cytokine IL-1β in the tumor microenvironment and serum have been associated with tumor growth, progression, angiogenesis, and recurrence in breast cancer (Soria et al. 2011). The IL-1β/IL-1 receptor (IL-1R)/β-catenin pathway increases cancer cell growth and metastasis, leading to higher expression of transcription factors, including SNAIL-1 and c-MYC. In addition, positive feedback in the tumor microenvironment promotes the levels of IL-1β and, unfortunately, carcinogenesis (Escobar et al. 2015). Moreover, it is demonstrated that IL-1β regulates the expression of COX-2, which plays a negative role in mammary lesions (Reed et al. 2009), and inhibition of IL-1/IL1R or knockdown of IL-1R reduced tumor progression. Our study’s final observation was that both drugs decreased IL-1β levels at all investigated doses (Fig. 5). Consistently, the expression levels of NLRP1 inflammasome components and caspase-1 activity were also reduced after the treatment of celecoxib, compared with untreated control, and these reduced levels of NLRP1 components were accompanied by lower IL-1β secretion (Figs. 3, 4 and 5). Our findings strongly indicate that celecoxib significantly inhibits NLRP1 inflammasome activation in MDA-MB-231 cells (Fig. 6). In previous studies, the significance of COX-2-dependent or -independent mechanisms in celecoxib-induced antiproliferative effects has been highlighted (Chen et al. 2009; Li et al. 2018; Nakatsugi et al. 2000; Shaik et al. 2004; Wen et al. 2020). Therefore, in our future studies, we aim to investigate the individual contributions of these two pathways to the inhibition of NLRP1 inflammasome activation, an underlying mechanism of celecoxib-induced anticancer effects. Moreover, knock-down and overexpression techniques are utilized to determine the therapeutic targets of drugs in human cancer cell lines. Therefore, genetically engineered cell lines can be used in our further study to investigate comprehensively whether the NLRP1 protein contributes to the antiproliferative effects of celecoxib in MDA-MB-231 cells. Interestingly, reduced IL-1β secretion induced by nimesulide was associated with neither higher expression of NLRP1 inflammasome components nor increased caspase-1 activity. The present study shows that while suppressing IL-1β may contribute to nimesulide’s antiproliferative effect, it may not be due to the NLRP1 inflammasome pathway.
The low cytotoxicity of celecoxib in healthy cells and its proven anti-tumor properties are promising regarding the repurposing of celecoxib as an anticancer drug. Our study has improved the knowledge of the underlying mechanism behind the anticancer properties of celecoxib. However, it is also crucial not to ignore celecoxib-related cardiotoxicity. Indeed, chronic use of a high dose of celecoxib (800 mg/day) might increase cardiovascular risk (Howes 2007). Therefore, using celecoxib in advanced cancer patients requires careful consideration of benefits and risks. Chen et al. conducted a meta-analysis and suggested that although the use of celecoxib exhibits crucial antitumor effects in cancer treatment, it also increases the risk of cardiovascular toxicity. The incidence of severe cardiovascular side effects was 1.78 times higher in the celecoxib group (Chen et al. 2014). It was reported that celecoxib at 500 mg/kg and higher doses significantly reduces tumor growth and volume in vivo breast cancer models (Li et al. 2018; Woditschka et al. 2008). In our study, the calculated IC50 value for celecoxib in MDA-MB-231 cells was 25.3 µM, higher than Cmax, ~ 600–900 ng/ml for 200 mg tablet (FDA 1998). However, further studies are necessary to determine the effective dose for treating breast cancer in humans and to investigate all potential adverse effects. In addition, developing less toxic and more effective drugs may be recommended by modifying the chemical structure of celecoxib, which has proven antitumor activity in preclinical and clinical studies.
Conclusions
It can be concluded that celecoxib inhibits the activation of the NLRP1 inflammasome by suppressing its component expression levels, inhibiting caspase-1 and IL-1β secretion. The NLRP1 inflammasome signaling pathway may be involved in celecoxib’s anti-proliferative and cytotoxic effects on MDA-MB-231 cells. Further research on different cell lines and in vivo models is needed to comprehensively understand the precise mechanism of celecoxib on breast cancer cells and investigate the novel mechanism proposed in the present study. The observations of the effects of nimesulide on the NLRP1 inflammasome are contradictory. Our results indicated that the inhibition of cell viability and migration induced by nimesulide in breast cancer is not associated with the NLRP1 inflammasome pathway.
Data availability
No datasets were generated or analysed during the current study.
Change history
06 August 2024
A Correction to this paper has been published: https://doi.org/10.1007/s00210-024-03348-5
References
Alle MD, Jones LJ (2015) The role of inflammation in the progression of breast cancer: friend or foe? (Review). Int J Oncol 47:797–805. https://doi.org/10.3892/ijo.2015.3075
Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD (2011) Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20:66–70. https://doi.org/10.1016/j.breast.2010.07.004
Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P (2005) Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7:R422–R435. https://doi.org/10.1186/bcr1019
Bennett A, Villa G (2000) Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother 1:277–286. https://doi.org/10.1517/14656566.1.2.277
Bocca C, Bozzo F, Bassignana A, Miglietta A (2011) Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 350:59–70. https://doi.org/10.1007/s11010-010-0682-4
Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L (2011) Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 22:1553–1561. https://doi.org/10.1007/s10552-011-9832-6
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. https://doi.org/10.1006/abio.1976.9999
Brandão RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, Tjan-Heijnen VC, Hupperets PS (2013) A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 15:R29. https://doi.org/10.1186/bcr3409
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. https://doi.org/10.1001/jama.295.21.2492
Chen B, Su B, Chen S (2009) A COX-2 inhibitor nimesulide analogue selectively induces apoptosis in Her2 overexpressing breast cancer cells via cytochrome c dependent mechanisms. Biochem Pharmacol 77:1787–1794. https://doi.org/10.1016/j.bcp.2009.03.015
Chen J, Shen P, Zhang XC, Zhao MD, Zhang XG, Yang L (2014) Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin Ther 36:1253–1263
Ciążyńska M, Bednarski IA, Wódz K, Narbutt J, Lesiak A (2020) NLRP1 and NLRP3 inflammasomes as a new approach to skin carcinogenesis. Oncol Lett 19:1649–1656. https://doi.org/10.3892/ol.2020.11284
Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55:429–434. https://doi.org/10.1136/jcp.55.6.429
Coussens M, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. https://doi.org/10.1038/nature01322
Dai ZJ, Ma XB, Kang HF, Gao J, Min WL, Guan HT, Diao Y, Lu WF, Wang XJ (2012) Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 2:53. https://doi.org/10.1186/1475-2867-12-53
Derry S, Moore RA (2013) Single dose oral celecoxib for acute postoperative pain in adults. The Cochrane Database Syst Rev 2013:CD004233. https://doi.org/10.1002/14651858.CD004233.pub4
Díaz-Cruz ES, Shapiro CL, Brueggemeier RW (2005) Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Meta 90:2563–2570. https://doi.org/10.1210/jc.2004-2029
Eibl G, Reber HA, Wente MN, Hines OJ (2003) The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 26:33–41. https://doi.org/10.1097/00006676-200301000-00007
Elangovan S, Hsieh TC, Wu JM (2008) Growth inhibition of human MDA-MB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product. Anticancer Res 28:2641–2647
Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Alexander HR (2006) The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12:1088–1096. https://doi.org/10.1158/1078-0432.CCR-05-1603
Escobar P, Bouclier C, Serret J, Bièche I, Brigitte M, Caicedo A, Sanchez E, Vacher S, Vignais ML, Bourin P, Geneviève D, Molina F, Jorgensen C, Lazennec G (2015) IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. Oncotarget 6:29034–29047. https://doi.org/10.18632/oncotarget.4732
FDA (1998) Celebrex. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20998lbl.pdf Accessed 20 October 2023
Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:241–247. https://doi.org/10.1038/ni.1703
Green DR, Kroemer G (2005) Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 115:2610–2617
Guo B, Fu S, Zhang J, Liu B, Li Z (2016) Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep 6:36107. https://doi.org/10.1038/srep36107
Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T (2000) Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 6:2006–2011
Howes LG (2007) Selective COX-2 inhibitors, NSAIDs and cardiovascular events-is celecoxib the safest choice? Ther Clin Risk Manag 3:831–845
Hua KF, Chou JC, Ka SM, Tasi YL, Chen A, Wu SH, Chiu HW, Wong WT, Wang YF, Tsai CL, Ho CL, Lin CH (2015) Cyclooxygenase-2 regulates NLRP3 inflammasome-derived IL-1β production. J Cell Physiol 230:863–874. https://doi.org/10.1002/jcp.24815
Jia T, Zhang L, Duan Y, Zhang M, Wang G, Zhang J, Zhao Z (2014) The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway. Cancer Cell Int 14:126. https://doi.org/10.1186/s12935-014-0126-4
Kantono M, Guo B (2017) Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol 8:1132. https://doi.org/10.3389/fimmu.2017.01132
Karki R, Kanneganti TD (2019) Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer 19:197–214. https://doi.org/10.1038/s41568-019-0123-y
Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M (2004) Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 18:300–310. https://doi.org/10.1096/fj.03-0473com
Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185. https://doi.org/10.1155/2014/149185
Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH (2003) The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 12:1486–1491
Li JY, Wang XZ, Chen FL, Yu JP, Luo HS (2003) Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol 9:915–920. https://doi.org/10.3748/wjg.v9.i5.915
Li J, Hao Q, Cao W, Vadgama JV, Wu Y (2018) Celecoxib in breast cancer prevention and therapy. Cancer Manag Res 10:4653–4667. https://doi.org/10.2147/CMAR.S178567
Lillo S, Saleh M (2022) Inflammasomes in cancer progression and anti-tumor immunity. Front Cell Dev Biol 10:839041. https://doi.org/10.3389/fcell.2022.839041
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563–18569
Masoud V, Pagès G (2017) Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol 8(2):120–134
Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, Sugie S, Sugimura T, Wakabayashi K (2000) Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 91:886–892. https://doi.org/10.1111/j.1349-7006.2000.tb01030.x
Pan Y, Zhang JS, Gazi MH, Young CY (2003) The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 12:769–774
Reed JR, Leon RP, Hall MK, Schwertfeger KL (2009) Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res 11:R21. https://doi.org/10.1186/bcr2246
Shaik MS, Chatterjee A, Singh M (2004) Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res 10:1521–1529. https://doi.org/10.1158/1078-0432.ccr-0902-03
Sharma BR, Kanneganti TD (2023) Inflammasome signaling in colorectal cancer. Transl Res 252:45–52. https://doi.org/10.1016/j.trsl.2022.09.002
Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A (2011) Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11:130. https://doi.org/10.1186/1471-2407-11-130
Strowig T, Henao-Mejia J, Elinav E, Flavell R (2012) Inflammasomes in health and disease. Nature 481:278–286. https://doi.org/10.1038/nature10759
Taabazuing CY, Griswold AR, Bachovchin DA (2020) The NLRP1 and CARD8 inflammasomes. Immunol Rev 297:13–25. https://doi.org/10.1111/imr.12884
Thi H, Hong S (2017) Inflammasome as a therapeutic target for cancer prevention and treatment. J Cancer Prev 22:62–73. https://doi.org/10.15430/JCP.2017.22.2.62
Wei Y, Huang H, Qiu Z, Li H, Tan J, Ren G, Wang X (2017) NLRP1 overexpression is correlated with the tumorigenesis and proliferation of human breast tumor. Biomed Res Int 2017:4938473. https://doi.org/10.1155/2017/4938473
Wen B, Wei YT, Mu LL, Wen GR, Zhao K (2020) The molecular mechanisms of celecoxib in tumor development. Medicine 99:e22544. https://doi.org/10.1097/MD.0000000000022544
Woditschka S, Haag JD, Mau B, Lubet RA, Gould MN (2008) Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model. Breast Cancer Res 10:R18. https://doi.org/10.1186/bcr1864
Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA, Fujita M (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 36:3820–3830. https://doi.org/10.1038/onc.2017.26
Acknowledgements
The Pharmaceutical Sciences Research Center (FABAL) Laboratory of Ege University, Faculty of Pharmacy was utilized to perform the Varioscan microplate reader.
Funding
Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK). This study was funded by Ege University Research Foundation (BAP) under grant number 22969.
Author information
Authors and Affiliations
Contributions
E.A. designed the study. E.A., D.B. and G.A. performed experiments and analysed the results. E.A. wrote the manuscript, and all authors contributed and approved the final manuscript. The authors confirm that they did not use any paper mill or artificial intelligence in their work. The authors declare that all data were generated in-house and that no paper mill was used.
Corresponding author
Ethics declarations
Ethics approval
No ethics approval was required.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Arzuk, E., Birim, D. & Armağan, G. Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells. Naunyn-Schmiedeberg's Arch Pharmacol (2024). https://doi.org/10.1007/s00210-024-03286-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00210-024-03286-2